Medtronic Leverages PR To Head Off Inversion Doubts
Medtronic Inc. has largely safeguarded its proposed $42.9 billion inversion from the political and social blowback that clouded a similar — but ill-fated — push by Pfizer Inc. earlier this year,...To view the full article, register now.
Already a subscriber? Click here to view full article